In patients with R/R CLL previously treated with ibrutinib, use of the CD19-directed CAR T-cell therapy lisocabtagene maraleucel was associated a high response rate and undetectable MRD along with low rates of grade ≥ 3 CRS and neurologic events.
Venetoclax/obinutuzumab produced significantly longer PFS and higher MRD negativity rates compared with chlorambucil/obinutuzumab in patients with previously untreated CLL and comorbidities.
Umbralisib monotherapy demonstrated clinical activity in patients with relapsed/refractory marginal zone lymphoma previously treated with CD20-directed therapy.
In patients with non-GCB DLBCL, the use of RLI followed by RLI plus chemotherapy produced high response rates and prolonged survival times that compared favorably with historical results.
Lenalidomide significantly decreased the risk of progression vs observation in patients with high-risk smoldering multiple myeloma.
Including ASCT after KRd induction therapy leads to higher persistent MRD negativity rate and reduces risk of early relapse in NDMM.
Iberdomide, a novel IMiD, was well tolerated and active in heavily pretreated patients with R/R MM.
The BiTE construct AMG 420 induces rapid clinical responses, including MRD negativity, in patients with relapsed/refractory multiple myeloma.